Mackenzie Financial’s Arbutus Biopharma ABUS Stock Holding History

Mackenzie Financial’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.95M	Buy	+613,806	New	+$2.7M	﹤0.01%	963
2020 Q4	–	Sell	-39,900	Closed	-$125K	–	1035
2020 Q3	$125K	Hold	39,900	–	–	﹤0.01%	946
2020 Q2	$73K	Hold	39,900	–	–	﹤0.01%	977
2020 Q1	$40K	Hold	39,900	–	–	﹤0.01%	1049
2019 Q4	$111K	Hold	39,900	–	–	﹤0.01%	1055
2019 Q3	$61K	Hold	39,900	–	–	﹤0.01%	994
2019 Q2	$83K	Hold	39,900	–	–	﹤0.01%	1077
2019 Q1	$143K	Hold	39,900	–	–	﹤0.01%	1194
2018 Q4	$153K	Hold	39,900	–	–	﹤0.01%	1101
2018 Q3	$377K	Hold	39,900	–	–	﹤0.01%	944
2018 Q2	$291K	Hold	39,900	–	–	﹤0.01%	896
2018 Q1	$200K	Hold	39,900	–	–	﹤0.01%	907
2017 Q4	$201K	Hold	39,900	–	–	﹤0.01%	800
2017 Q3	$247K	Hold	39,900	–	–	﹤0.01%	579
2017 Q2	$144K	Hold	39,900	–	–	﹤0.01%	601
2017 Q1	$130K	Hold	39,900	–	–	﹤0.01%	618
2016 Q4	$98K	Hold	39,900	–	–	﹤0.01%	631
2016 Q3	$137K	Hold	39,900	–	–	﹤0.01%	624
2016 Q2	$139K	Hold	39,900	–	–	﹤0.01%	900
2016 Q1	$165K	Hold	39,900	–	–	﹤0.01%	779
2015 Q4	$178K	Hold	39,900	–	–	﹤0.01%	787
2015 Q3	$243K	Hold	39,900	–	–	﹤0.01%	757
2015 Q2	$473K	Hold	39,900	–	–	﹤0.01%	685
2015 Q1	$697K	Buy	+39,900	New	+$817K	﹤0.01%	606

Other funds holding ABUS

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Mackenzie Financial's ABUS Position: Q2 2026 in Review

Mackenzie Financial opened a new position in Arbutus Biopharma (ABUS) in Q2 2026: 613,806 shares worth $2.95M. The stake represents ﹤0.01% of the portfolio and ranks #963 among its holdings. This is a return to the name: Mackenzie Financial previously reported a position in ABUS as recently as Q3 2020.

Mackenzie Financial first reported a position in ABUS in Q1 2015 and has held it in 24 quarters since. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

Mackenzie Financial held 613,806 shares of Arbutus Biopharma worth $2.95M as of Q2 2026.
Arbutus Biopharma was a new Mackenzie Financial position in Q2 2026.
Arbutus Biopharma made up ﹤0.01% of Mackenzie Financial's portfolio in Q2 2026, its #963 holding.
Mackenzie Financial first reported a position in Arbutus Biopharma in Q1 2015 and has held it in 24 quarters since.
177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.